Shiraz Yussaf, MD
Family Medicine · Hoboken, NJNPI 1134448251
Payments from drug & device makers
Across 460 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$958
- Amgen$743
- GSK$501
- Pfizer$367
- Novartis$323
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,00099%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,152 |
| AstraZeneca | 55 | $958 |
| Amgen(2 entities) | 57 | $743 |
| GSK | 36 | $501 |
| Pfizer | 24 | $367 |
| Novartis | 20 | $323 |
| Gilead | 20 | $304 |
| Lilly USA, LLC | 20 | $283 |
| Bayer | 14 | $271 |
| Abbott | 11 | $211 |
| Exact Sciences | 7 | $193 |
| Sanofi-aventis U.S. LLC | 14 | $193 |
| Medtronic | 6 | $176 |
| Johnson & Johnson | 12 | $171 |
| AbbVie(2 entities) | 12 | $167 |
| Merck | 11 | $147 |
| Boehringer Ingelheim | 10 | $139 |
| Mylan Specialty L.p. | 7 | $110 |
| Arbor Pharmaceuticals, Inc. | 6 | $89 |
| Amarin Pharma, Inc. | 6 | $85 |
| Vivus LLC | 5 | $75 |
| Astellas Pharma US Inc | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Dexcom, Inc. | 1 | $33 |
| Azurity Pharmaceuticals, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Sun Pharmaceutical Industries Inc. | 2 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Mannkind Corporation | 2 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Eisai Inc. | 1 | $12 |
How this compares
$7,043 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 578 | $219,843 |
| OzempicSemaglutide | 44 | $65,930 |
| JanuviaSitagliptin Phosphate | 124 | $64,543 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $63,421 |
| MounjaroTirzepatide | 38 | $47,784 |
| EntrestoSacubitril/Valsartan | 62 | $45,328 |
| FarxigaDapagliflozin Propanediol | 33 | $43,448 |
| TrulicityDulaglutide | 40 | $42,107 |
| XareltoRivaroxaban | 100 | $41,179 |
| MyrbetriqMirabegron | 95 | $33,135 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $22,142 |
| JardianceEmpagliflozin | 28 | $21,479 |
| LinzessLinaclotide | 29 | $20,727 |
| VascepaIcosapent Ethyl | 50 | $19,589 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $15,655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $367 | $219,843578 claims |
| Lilly USA, LLCMounjaro, Trulicity | $283 | $89,89178 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $501 | $85,563104 claims |
| MerckJanuvia, Lagevrio (Eua) | $147 | $74,526145 claims |
| Novo NordiskOzempic | $1,152 | $65,93044 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $958 | $59,10354 claims |
| Johnson & JohnsonXarelto, Procrit | $171 | $55,368116 claims |
| NovartisEntresto | $323 | $45,32862 claims |
| Astellas Pharma US IncMyrbetriq | $59 | $33,13595 claims |
| AbbVieLinzess, Combigan, Lumigan | $167 | $31,17963 claims |
| Boehringer IngelheimJardiance, Tradjenta | $139 | $28,82556 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Hoboken
- Gaurang BrahmbhattHoboken$2.6M
- Gregory TraceyHoboken$181K
- Juan LatorreHoboken$71K
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.